Research at NUCLEATE

Interdisciplinary research spanning biology, chemistry, pharmacy, medicine, computation and technology.

Research Program

NUCLEATE’s vision is to unlock the full potential of nucleic acids, towards a new understanding of their role in biology and to pave the way for nucleic acid medicine.

This video was created using AI.
This video was created using AI.

Research Focus

NUCLEATE pursues a systematic and innovative approach to nucleic acid research. The aim is to study RNA and DNA molecules not only in their classic role as information storage devices, but also as active regulators and tools. The focus is on three perspectives: nucleic acids as subjects (active molecular actors), as objects (targets of biological regulation), and as tools (basis for therapeutic or technological applications). This conceptual tripartite division allows for a novel structuring of research approaches within the cluster. A particular focus is on elucidating previously unexplored RNA functions, characterizing regulatory networks, and developing new nucleic acid-based technologies, including genome editing, RNA inhibitors, synthetic therapeutics, and diagnostic tools.

An integrated vision of nucleic acid research uniting their roles as subjects, objects, and tools to break down disciplinary silos and foster innovation. © SCIGRAPHIX, Dr. Sandy Westermann.
Research Area A

Emerging Nucleic Acid Functions

Area A will encompass the study of nucleic acids as subjects that execute diverse functions beyond the classical paradigm of information storage. These studies will be conducted across different domains of life and viruses, yet with a special focus on human biology and disease.

A1

Research Field

Regulators & Guides

Regulatory nucleic acids shape cellular functions through sequence-guided interactions that control biological processes.

A2

Research Field

Catalysts & Scaffolds

Elucidate novel catalytic and scaffolding properties of different RNA classes and characterize their interplay with viral and disease-associated factors.

A3

Research Field

Ligands & Signaling Molecules

Nucleic acids and their key role in the formation of regulatory codes.

A4

Research Field

Regulatory Code

The dynamic organization of the genome integrates developmental and environmental signals to control gene expression and cellular adaptation.

Research Area B

Nucleic Acid Metabolism & Homeostasis

In Area B, nucleic acids are seen as objects that are modified, processed, metabolized, or regulated by dedicated quality control mechanisms. We will investigate how these mechanisms affect NA functionality during genetic information storage, transcription, and translation.

B1

Research Field

Chemical Modifications

Chemical modifications create a regulatory layer that connects nucleic acid chemistry to gene expression.

B2

Research Field

Processing & Metabolism

Understanding the "mRNP code" that determines the fate, function, and regulation of messenger RNAs.

B3

Research Field

Quality Control Mechanisms

Nucleic acid quality control safeguards genome integrity by detecting and resolving damage, errors, and stress.

Research Area C

Nucleic Acid Technologies & Medicine

Area C will encompass the development of computational approaches and nucleic acids as tools that can help garner new biological insights and form the basis of next-generation diagnostics and therapies.

C1

Research Field

Computational Biology

AI models uncover the regulatory grammar of nucleic acids across genomes, cells, and populations.

C2

Research Field

Technologies & Diagnostics

Programmable nucleic acids enable powerful technologies for probing, recording, and engineering biological systems.

C3

Research Field

Therapeutics

Nucleic acid medicines are transforming therapeutic strategies through targeted modulation of genes and RNA.

United across Institutions and Disciplines

People

NUCLEATE brings together research groups across LMU München, TU Munich and JMU Würzburg working at the forefront of nucleic acid science.

We conduct fundamental research ranging from fundamental molecular mechanisms to innovative RNA-based technologies with translational potential.

Filter by research field
A2
B1
B3
Principal Investigator

Prof. Dr.

Roland Beckmann

Chair of Cellular Biochemistry, Gene Center and Department of Biochemistry, Faculty of Chemistry and Pharmacy

Ludwig-Maximilians-Universität München

B2
Affiliated Group

Dr.

Irene Beusch

Research Group Leader "RNA Splicing Mechanisms", Institute of Molecular Infection Biology, Faculty of Medicine

Julius-Maximilians-Universität Würzburg

B2
B3
Affiliated Group

Dr.

Jonathan Bohlen

Research Group Leader "mRNA Translation in Human Immunity", Gene Center and Department of Biochemistry, Faculty of Chemistry and Pharmacy

Ludwig-Maximilians-Universität München

A3
B2
B3
Associated Investigator

Prof. Dr.

John Briggs

Director Department Cell and Virus Structure

Max-Planck-Institut für Biochemie

PhD

Jonas Busam

Zarnack Lab
Julius-Maximilians-Universität Würzburg

C3
Associated Investigator

Prof. Dr.

Alena Buyx

Chair of Ethics in Medicine and Health Technologies, Institute of History and Ethics in Medicine, TUM School of Medicine and Health

Technische Universität München

B1
C3
Principal Investigator

Prof. Dr.

Thomas Carell

Chair of Organic Chemistry, Institute of Chemical Epigenetics and Department of Chemistry, Faculty of Chemistry and Pharmacy

Ludwig-Maximilians-Universität München

PhD

Hsuan-Ai Chen

Höbartner Lab
Julius-Maximilians-Universität Würzburg

C1
Associated Investigator

Prof. Dr.

Maria Colomé-Tatché

Biomedical Center and Department Physiological Chemistry, Faculty of Medicine

Ludwig-Maximilians-Universität München

B2
Principal Investigator

Prof. Dr.

Elena Conti

Director Department Structural Cell Biology

Max-Planck-Institut für Biochemie

Postdoc

Dr.

Miona Corovic

König Lab
Julius-Maximilians-Universität Würzburg

A3
Principal Investigator

Prof. Dr.

Carina de Oliveira Mann

Professor of Biomolecular Cryo-Electron Microscopy, Center for Functional Protein Assemblies, TUM School of Natural Sciences

Technische Universität München

A1
A4
C3
Principal Investigator
Speaker
Steering Committee

Prof. Dr. Dr.

Stefan Engelhardt

Chair of Pharmacology and Toxicology, Director
Institute of Pharmacology and Toxicology
TUM School of Medicine and Health

Technische Universität München

A1
C3
Associated Investigator

Prof. Dr.

Franziska Faber

Professor for Microbial Interactions, Institute for Hygiene and Microbiology, Faculty of Medicine

Julius-Maximilians-Universität Würzburg

C1
Principal Investigator

Prof. Dr.

Fabian Theis

Chair of Mathematical Modelling of Biological Systems, Director, Institute of Computational Biology and Department of Mathematics, TUM School of Computation, Information and Technology

Helmholtz Zentrum München and Technische Universität München

A2
B2
C2
Principal Investigator

Prof. Dr.

Utz Fischer

Chair of Biochemistry I, Theodor Boveri Institute, Biocenter, Faculty of Chemistry and Pharmacy

Julius-Maximilians-Universität Würzburg

PhD

Ann-Katrin Fuchs

Kisker Lab
Julius-Maximilians-Universität Würzburg

C2
C3
Associated Investigator

Prof. Dr.

Julian Grünewald

Professor of Gene Editing, TUM Center for Organoid Systems and Klinik und Poliklinik für Innere Medizin I, TUM School of Medicine and Health

TUM Universitätsklinikum

PhD

Famke Guder

Beusch Lab
Julius-Maximilians-Universität Würzburg

Postdoc

Dr.

Fergal Hamrock

Faber Lab
Julius-Maximilians-Universität Würzburg

B2
Associated Investigator

Prof. Dr.

Vigo Heissmeyer

Biomedical Center and Institute for Immunology, Faculty of Medicine

Ludwig-Maximilians-Universität München

Postdoc

Dr.

Peter Hoch-Kraft

König Lab
Julius-Maximilians-Universität Würzburg

A3
B3
Principal Investigator
Steering Committee

Prof. Dr.

Karl-Peter Hopfner

Chair of Biochemistry, Gene Center and Department of Biochemistry, Faculty of Chemistry and Pharmacy

Ludwig-Maximilians-Universität München

A3
Principal Investigator
Speaker
Steering Committee

Prof. Dr.

Veit Hornung

Chair of Immunobiochemistry, Gene Center and Department of Biochemistry, Faculty of Chemistry and Pharmacy

Ludwig-Maximilians-Universität München

B3
Associated Investigator

Prof. Dr.

Christian Häring

Chair of Biochemistry and Cell Biology, Theodor Boveri Institute, Biocenter, Faculty of Medicine

Julius-Maximilians-Universität Würzburg

A2
B1
B2
B3
C2
Principal Investigator

Prof. Dr.

Claudia Höbartner

Chair of Organic Chemistry I, Institute of Organic Chemistry, Faculty of Chemistry and Pharmacy

Julius-Maximilians-Universität Würzburg

PhD

Gheo Idrissou

Technische Universität München
Engelhardt Lab

Postdoc

Dr.

Aman Ishaqat

Engelhardt Lab
Technische Universität München

Postdoc

Dr.

Marvin Jungblut

Julius-Maximilians-Universität Würzburg
Zimmer Lab

Postdoc

Dr.

Takeshi Kanda

Westermann Lab
Julius-Maximilians-Universität Würzburg

C1
Principal Investigator

Prof. Dr.

Sarah Kim-Hellmuth

Independent Research Group Leader, Department of Pediatrics and Institute of Translational Genomics

Klinikum der Ludwig-Maximilians-Universität München and Helmholtz Zentrum München

B3
Principal Investigator
Steering Committee

Prof. Dr.

Caroline Kisker

Chair of Structural Biology, Rudolf-Virchow-Zentrum, Center for Integrative and Translational Bioimaging and Faculty of Medicine

Julius-Maximilians-Universität Würzburg

Postdoc

Dr.

Jochen Kuper

Kisker Lab
Julius-Maximilians-Universität Würzburg

A2
B1
Associated Investigator

Prof. Dr.

Julian König

Chair of Biochemistry and RNA Biology, Theodor Boveri Institute, Biocenter, Faculty of Medicine

Julius-Maximilians-Universität Würzburg

A4
Principal Investigator

Prof. Dr.

Andreas Ladurner

Chair of Physiological Chemistry, Biomedical Center, Faculty of Medicine

Ludwig-Maximilians-Universität München

PhD

Annika Ladwig

Zarnack Lab
Julius-Maximilians-Universität Würzburg

Postdoc

Dr.

Isotta Lorenzi

Fischer Lab
Julius-Maximilians-Universität Würzburg

C3
Principal Investigator

Prof. Dr.

Lars Maegdefessel

Chair of Molecular Vascular Medicine, Director, Institute of Molecular Vascular Medicine, TUM School of Medicine and Health

TUM Universitätsklinikum

C1
Associated Investigator

Prof. Dr.

Annalisa Marsico

Research group leader, Institute of Computational Biology, Computational Health Center

Helmholtz Zentrum München

C3
Associated Investigator

Prof. Dr.

Steffen Massberg

Department of Medicine I, Medizinische Klinik und Poliklinik I

Klinikum der Ludwig-Maximilians-Universität München

C3
Principal Investigator

Prof. Dr.

Olivia Merkel

Chair of Drug Delivery, Department of Pharmacy, Faculty of Chemistry and Pharmacy

Ludwig-Maximilians-Universität München

A1
C3
Principal Investigator

Prof. Dr.

Alessandra Moretti

Chair of Regenerative Medicine in Cardiovascular Disease, Klinik und Poliklinik für Innere Medizin I, TUM School of Medicine and Health

TUM Universitätsklinikum

A3
B2
A1
Principal Investigator

Prof. Dr.

Andreas Pichlmair

Professor of Viral Immunopathology, Institute of Virology, TUM School of Medicine and Health

Technische Universität München

A3
B2
C3
Principal Investigator

Prof. Dr.

Ulrike Protzer

Chair of Virology, Director, Institute of Virology, TUM School of Medicine and Health

Technische Universität München

Postdoc

Dr.

Archana Prusty

Fischer Lab
Julius-Maximilians-Universität Würzburg

A2
A1
C3
Principal Investigator

Prof. Dr.

Roland Rad

Chair of Molecular Oncology and Functional Genomics, Director, Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine and Health

TUM Universitätsklinikum

PhD

Nandana Rajendran

Beusch Lab
Julius-Maximilians-Universität Würzburg

B1
C2
Associated Investigator

Prof. Dr.

Andrea Rentmeister

Chair of Organic and Biological Chemistry, Department of Chemistry, Faculty of Chemistry and Pharmacy

Ludwig-Maximilians-Universität München

C1
Associated Investigator

Prof. Dr.

Emmanuel Saliba

Professor Single Cell Analysis, Institute of Molecular Infection Biology, Faculty of Medicine and Group Leader, Helmholtz Institute of RNA-based Infection Research (HIRI)

Julius-Maximilians-Universität Würzburg and Helmholtz Institut für RNA-basierte Infektionsforschung (HIRI)

A2
B2
C3
Principal Investigator
Steering Committee

Prof. Dr.

Michael Sattler

Chair of Biomolecular NMR-Spectroscopy, Director, Institute of Structural Biology and Bavarian NMR Center, Department of Bioscience, TUM School of Natural Sciences, Head of Helmholtz Molecular Targets & Therapeutics Center

Technische Universität München und Helmholtz Munich

PhD

Julia Seidel

Vogel Lab
Julius-Maximilians-Universität Würzburg

Postdoc

Sahil Sharma

Sharma Lab
Julius-Maximilians-Universität Würzburg

B2
A1
C2
Principal Investigator
Speaker
Steering Committee

Prof. Dr.

Cynthia Sharma

Chair of Molecular Infection Biology II, Institute of Molecular Infection Biology, Faculty of Medicine

Julius-Maximilians-Universität Würzburg

A4
C2
Associated Investigator

Prof. Dr.

Nicolai Siegel

Biomedical Center and Department of Physiological Chemistry, Faculty of Veterinary Medicine

Ludwig-Maximilians-Universität München

B3
Associated Investigator

Prof. Dr.

Julian Stingele

Chair of Cellular Biochemistry, Gene Center and Department of Biochemistry, Faculty of Chemistry and Pharmacy

Ludwig-Maximilians-Universität München

PhD

Dominik Stroh

Zarnack Lab
Julius-Maximilians-Universität Würzburg

B1
A4
Associated Investigator

Prof. Ph.D.

Kikuë Tachibana

Director Department of Totipotency

Max-Planck-Institut für Biochemie

A4
Principal Investigator

Prof. Dr.

Maria-Elena Torres-Padilla

Director Institute of Epigenetics and Stem Cells

Helmholtz Zentrum München and Ludwig-Maximilians-Universität München

Postdoc

Dr.

Reginald van der Kwast

Engelhardt Lab
Technische Universität München

A1
C3
Principal Investigator

Prof. Dr.

Jörg Vogel

Chair of Molecular Infection Biology I, Director Institute of Molecular Infection Biology and Director, Helmholtz Institute for RNA-based Infection Research, Faculty of Medicine

Julius-Maximilians-Universität Würzburg and Helmholtz Institut für RNA-basierte Infektionsforschung (HIRI)

B2
A1
Associated Investigator

Prof. Dr.

Alexander Westermann

Professor at the Department of Microbiology, Theodor Boveri Institute, Biocenter, Faculty of Biology

Julius-Maximilians-Universität Würzburg

A2
C1
B2
Associated Investigator

Prof. Dr.

Kathi Zarnack

Chair of Bioinformatics II, Theodor Boveri Institute, Biocenter, Faculty of Biology

Julius-Maximilians-Universität Würzburg

C1
C3
Associated Investigator

Prof. Dr.

Eleftheria Zeggini

Professor of Translational Genomics, Institute of Translational Genomics, Computational Health Center

Helmholtz Zentrum München

B3
A4
Associated Investigator

Prof. Dr.

Christophe Zimmer

Chair of Machine Biophotonics, Rudolf-Virchow-Zentrum, Center for Integrative and Translational Bioimaging, Faculty of Medicine

Julius-Maximilians-Universität Würzburg

NUCLEATE Cluster

Publications

SAM68 is a multifunctional post-transcriptional regulator of cardiomyocyte differentiation.

Broglia, L.; Dasti, A.; Antonelli, MC.; Aoun, G.; D'Agostino, S.; Vandelli, A.; Armaos, A.; Delli Ponti, R.; Wolf, S.; Klostermann, M.; Arnal Segura, M.; Tian, TV.; Mariani, D.; Colantoni, A.; Paronetto, MP.; Gustincich, S.; Zarnack, K.; Bechara, E.; Tartaglia, GG.

Nucleic Acids Res. · 2026

Show abstract

RNA-binding proteins (RBPs) of the STAR family play key roles in mammalian development, yet their contributions to lineage specification remain incompletely understood. Here, using CRISPR-Cas9 knockout models combined with multi-omics approaches, we investigate the functions of two STAR proteins, SAM68 and QKI, in mouse embryonic stem cells (mESCs). Both RBPs support mESC proliferation, self-renewal, and efficient differentiation into cardiomyocytes. Although SAM68 and QKI belong to the same protein family, they control largely distinct regulatory programs during differentiation. We uncover an unexpected role for SAM68 in cardiomyocyte specification through multiple post-transcriptional mechanisms. SAM68 modulates alternative splicing and promotes the biogenesis of a subset of cardiac-enriched circular RNAs, through binding to intronic regions flanking back-splice junctions and potentially through association with NF90/110. In addition, SAM68 binds untranslated regions of key differentiation-related transcripts, including Gata4 mRNA, and functions in ribonucleoprotein complexes to regulate their translation. Together, these findings identify SAM68 as a multifunctional regulator coordinating multiple layers of RNA metabolism-including splicing, circRNA biogenesis, and translation-during cardiomyocyte differentiation and provide insight into how STAR proteins shape post-transcriptional gene regulatory networks during early development.

Alkyltransferase Ribozyme for Site-Specific N-Cytidine Alkylation.

Dorinova, E.; Walunj, MB.; Höbartner, C.

Angew Chem Int Ed Engl. · 2026

Show abstract

Ribozymes for site-specific RNA modification provide an elegant approach for the installation of diverse functional groups, fluorophores, affinity tags, or crosslinkers at defined positions within an RNA of interest. There is increasing interest in expanding the ribozyme toolbox, since recently reported in vitro selected ribozymes have been mostly limited to labeling at adenosine sites, either by alkylation of the nucleobase or phosphodiester formation at the 2'-OH group. Here we report a cytidine-specific alkyltransferase ribozyme (CSAR) that uses O-benzylguanines as alkyl group donors. CSAR is the first ribozyme that catalyzes direct alkylation of the exocyclic amino group of a nucleobase and generates N-alkylated cytidine in a defined sequence context of a short RNA hairpin loop. In combination with tuning the electronic parameters of the transferred benzyl group, CSAR enables highly efficient cytidine alkylation for the installation of bioorthogonal functional groups.

Respiratory syncytial viral load drives ciliated cell dedifferentiation and suppresses antiviral immunity.

Berg, K.; Haid, S.; Vafadarnejad, E.; Carpentier, A.; Geffers, R.; Wiegmann, B.; Saliba, AE.; Erhard, F.; Pietschmann, T.

Sci Adv. · 2026

Show abstract

Respiratory syncytial virus (RSV) causes severe lower respiratory disease, yet how it reshapes airway epithelial cells and evades innate immunity remains incompletely understood. We infected adult primary human airway epithelial cultures with RSV and analyzed infected and bystander cells over time using single-cell RNA sequencing and imaging. RSV mainly infected ciliated cells, triggering a virus load-dependent shutdown of genes involved in ciliogenesis, antigen presentation, and innate sensing, including key interferon (IFN) and pattern recognition pathways. Only a subset of infected cells produced type I and III IFNs, while bystander cells exhibited strong IFN-stimulated gene (ISG) signatures. Neither IFN treatment nor ISG induction eliminated infection, but IRF1, an antiviral transcription factor not suppressed by RSV, remained robustly expressed. Ectopic IRF1 expression in vitro reduced viral replication. These findings reveal how RSV evades antiviral defenses and highlight IRF1 as a potential target for therapeutic intervention.

The impact of read depth and read length on RNA-seq splicing analysis.

Ladwig, A.; Klostermann, M.; Zarnack, K.

RNA. · 2026

Show abstract

Alternative splicing (AS) is a key layer of regulation in eukaryotic gene expression that is investigated in all areas of life sciences. Differences in AS between conditions can be quantified from transcriptome-wide short-read RNA sequencing (RNA-seq) data with designated computational tools. However, not all short-read RNA-seq data are equally suited for AS analysis. Here, we perform an exemplary AS analysis to showcase the impact of the RNA-seq library characteristics on the obtained results. Using two standard ENCODE data sets with widespread AS changes, we modulate read length and read depth and compare their influence on the detection, quantification, and classification of AS events with the state-of-the-art AS algorithm MAJIQ. We find that both longer reads and higher read depth are effective measures to improve the sensitivity and precision of the AS analysis. Our results provide valuable insights to help researchers make informed decisions when choosing the short-read RNA-seq library specifications for AS analysis.

BNB/NBN-Phenalenyl-2'-deoxyuridines as a Fluorophore-Quencher Pair in DNA.

Lutz, S.; Neitz, H.; Müller, M.; Chorbacher, J.; Isenberg, KA.; Höbartner, C.; Helten, H.

Angew Chem Int Ed Engl. · 2026

Show abstract

Deoxyribonucleic acid (DNA) enables the precise arrangement and positioning of chromophores in order to study their interactions, leading, for example, to through-space energy transfer processes. BNB- and NBN-doped phenalenyls are electronically complementary fluorophores that are neutral BN/CC isosteres of the phenalenyl cation and anion, respectively. Herein, we present a pair of BNB- and NBN-doped phenalenyl-extended nucleosides, which we introduced into DNA via phosphoramidite chemistry. The two chromophores act as a donor-acceptor pair in a Förster resonance energy transfer (FRET) process, which results in the quenching of the BNB-phenalenyl fluorescence due to the nonradiative decay of the charge transfer (CT) state of the NBN-phenalenyl acceptor in an aqueous environment. The DNA duplex serves as a supramolecular scaffold to control the arrangement of the interacting BNB- and NBN-doped chromophores. The performance of the fluorophore-quencher pair was evaluated in a toehold-mediated strand displacement (TMSD) experiment, demonstrating its potential for DNA-based applications.

From random pools to precision tools: The expanding repertoire of synthetic nucleic acid catalysts.

Scheitl, CPM.; Höbartner, C.

Curr Opin Chem Biol. · 2026

Show abstract

Synthetic nucleic acid catalysts serve as powerful tools to interrogate and manipulate biological processes with high specificity. Advances in in vitro selection, high-throughput sequencing, and computational design have yielded increasingly efficient and chemically diverse ribozymes and deoxyribozymes. Beyond applications in nucleic acid research and diagnostics, the study of nucleic acid catalysts offers fundamental insights into the origin of life and the RNA world hypothesis. This review covers both fundamental and applied perspectives and summarizes recent advancements in the field of in vitro evolution and the development of synthetic ribozymes and DNAzymes. The topics include the latest research on RNA-ligases and polymerase ribozymes as well as ribozymes and DNAzymes for targeted modification of RNA and peptides including novel catalysts for site-specific methylation, alkylation, and acylation. Finally, the versatility of RNA-cleaving DNAzymes as sensors and for the detection of RNA modifications, as well as the ability of DNAzymes to catalyze light-activating reactions are presented.

A lipid "glue" for STING oligomers.

Sun, Z.; Hornung, V.

Cell Res. · 2026

A human-specific long noncoding RNA regulator of antigen-presenting cell viability and antimicrobial defense.

Westermann, AJ.; Schock, A.; Ashour, DAD.; Wende, S.; Skevaki, C.; Mack, E.; Schmeck, B.; Linne, U.; Herrmann, T.; Antonakos, N.; Florou, H.; Giamarellos-Bourboulis, EJ.; Weis, S.; Vogel, J.; Schulte, LN.

Proc Natl Acad Sci U S A. · 2026

Show abstract

Macrophages are essential for both, to clear pathogens and preserve tissue homeostasis, yet the molecular regulators of this equilibrium remain incompletely defined. Here, we identify SAILR (survival associated immune-regulatory RNA), a primate-specific long noncoding RNA (lncRNA), as a critical modulator of macrophage viability under infection conditions. SAILR is induced during monocyte-to-macrophage differentiation, but rapidly downregulated upon bacterial challenge in a nuclear factor kappa B (NF-κB) dependent manner. In both naïve and immune-activated macrophages, SAILR dampens the expression of adhesion, phagocytosis, and invasion factors, which include SIGLEC1 and MMP7. During infection with Typhimurium, depletion of SAILR sensitizes macrophages to apoptosis, resulting in loss of intracellular replication niches and reduced bacterial recovery. Conversely, enforced SAILR expression promotes macrophage survival and increases intracellular pathogen burden. Mechanistically, SAILR interacts with the antiapoptotic adaptor protein 14-3-3β to support macrophage survival. Notably, downregulation of SAILR is mirrored in circulating immune cells from patients with severe COVID-19 and sepsis. Together, our findings position SAILR as a central regulator in linking macrophage survival to host-pathogen interaction and disease pathophysiology.

Machine learning and language models for RNA structure prediction: Progress and perspectives.

Moyon, L.; Marsico, A.

Curr Opin Struct Biol. · 2026

Show abstract

RNA structure is central to the function of every RNA class yet the gap between annotated sequences and experimentally determined structures remains large. Computational methods to fill this gap have evolved from thermodynamic free energy minimization through supervised deep learning to self-supervised RNA language models trained on millions of sequences, progressively improving structure prediction. Here we review the state of the art in RNA structure prediction, covering key training datasets, community benchmarks, and the performance of current models. We further discuss perspectives on integrating other data modalities, such as chemical probing signals and RNA modifications, as well as the emerging role of generative models. Challenges in generalization, handling of noncanonical interactions, and contextual structure prediction remain open frontiers for the field.

A magic methyl effect in the active site of a methyltransferase ribozyme.

Aupič, J.; Chen, HA.; Scheitl, CPM.; Höbartner, C.; Magistrato, A.

Nat Commun. · 2026

Show abstract

The chemical richness of RNAs is greatly enhanced by post-transcriptional modifications with RNA methylation as the most prominent type. RNA modifications modulate the stability, folding and interaction pattern of RNA molecules. Furthermore, emerging data suggests RNA modifications also directly regulate the activity of catalytic RNA molecules, i.e., ribozymes. Here, we employ classical and hybrid quantum-classical (QM/MM) molecular dynamics (MD) simulations to investigate the reaction mechanism of an artificial methyltransferase ribozyme MTR1. Importantly, we pinpoint how 2'-O-methylations of active site nucleotides synergistically enhance ribozyme activity by reducing the conformational flexibility of the ribose rings and rigidifying the active site. Finally, the herein reported crystal structure of the modified MTR1, solved at 2.6 Å resolution, validates the results of our simulations. Taken together, our work supports the purported central role of modified RNA for early RNA catalysis and may guide rational design of more efficient ribozymes.

Isotope-free mapping of protein-RNA interactions at single-nucleotide resolution by iCLIP3.

Despic, V.; Klostermann, M.; Orekhova, A.; Mesitov, M.; Busch, A.; Zarnack, K.; König, J.; Müller-McNicoll, M.

STAR Protoc. · 2026

Show abstract

Individual-nucleotide resolution UV crosslinking and immunoprecipitation (iCLIP) enables transcriptome-wide mapping of RNA-binding protein (RBP)-RNA interactions. Here, we present iCLIP version 3 (iCLIP3), a streamlined protocol optimized for generating high-quality iCLIP libraries from low-input material. We describe steps for near-infrared visualization of RBP-RNA complexes, silica column-based RNA isolation, and unique dual indexing using TruSeq adapters for cost-effective multiplexing and sequencing. We detail a complete bioinformatics workflow to identify crosslinking events and define RBP binding sites from raw sequencing data.

RNA motifs, RNA structure, and motif context analyzed by RNAanalyzer3.

Akash, A.; Balkenhol, J.; Liang, C.; Zarnack, K.; Dandekar, T.

Nucleic Acids Res. · 2026

Show abstract

RNAanalyzer3 ("RNA analyzer cubic"; https://rnaanalyzer.bioapps.biozentrum.uni-wuerzburg.de) substitutes the frequently consulted current RNAanalyzer webserver (https://rnaanalyzer-old.bioapps.biozentrum.uni-wuerzburg.de). RNAanalyzer3 is free/open via the secure HTTPS protocol, with example data, help and tutorial, web-link to results, and rich data output. We combine a general detailed structure analysis with motif analyses. It accepts either a single plain-text nucleotide sequence or batch submission in FASTA format, which can be pasted or uploaded as a FASTA file. Our tool (i) has up-to-date software and operating systems, (ii) combines diverse RNA motif analyses with RNA structure prediction, (iii) puts found motifs into structural context, and (iv) offers dedicated tools for probing RNA-protein binding interactions. RNAanalyzer3 links motif searches to Rfam and miRNA search to miRbase. It focuses on structural features first, looks for stem-loops, hairpins, and specific enrichment regions such as stem-GG pairs, plus AU-rich regions with their locations for easier identification, while providing structural context and interactive RNA structure visualization. A tabulated overview shows all RNA features including structure details, coding potential, untranslated regions (UTRs, including Shine-Dalgarno sequences, Kozak sequences, and polyadenylation signals), transfer RNA (tRNA), microRNA (miRNA), long noncoding RNA (lncRNA), trans-splicing motifs, iron response elements (IRE), riboswitches, small nuclear ribonucleoprotein (snRNP) motifs, and spliceosomal Sm-sites.

The dark genome in cardiovascular medicine.

Kesidou, D.; Brown, SD.; Maegdefessel, L.; Ulitsky, I.; Baker, AH.

Eur Heart J. · 2026

Show abstract

Only ∼1%-2% of the human genome directly codes for proteins. The remainder consists of non-coding DNA, often referred to as the 'dark genome'. This includes regulatory elements, transposable and repetitive sequences, structural genomic features, pseudogenes, intronic and intergenic regions, and non-coding RNA (ncRNA) genes. These components are increasingly recognized as major regulators of gene expression, cell identity, and disease susceptibility. Currently, dark genome elements, particularly ncRNAs are increasingly recognized as important regulators of cardiovascular health and disease. Advances in genome analysis technologies have greatly improved our understanding of these non-coding regions and revealed clearer connections between the dark genome and cardiovascular traits. This review highlights major parts of the dark genome involved in cardiovascular disease, with emphasis on those for which mechanistic understanding and translational relevance are beginning to emerge. As mechanistic insight into individual and collective components of the dark genome advances, it increasingly enables the development of new opportunities for targeted therapeutics for cardiovascular prevention and disease management.

Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy.

Kadel, SK.; Scheller, L.; Leipold, AM.; Krammer, T.; Raskó, T.; Alb, M.; Weis, P.; Leberzammer, M.; Schmitt, F.; Stetter, C.; Tamamushi, Y.; Köck, A.; Köberle, P.; Reich, M.; Musacchio, T.; Doppler, K.; Sommer, C.; Cebulla, N.; McFleder, R.; Ip, CW.; Volkmann, J.; Kallius, M.; Serfling, SE.; Hartrampf, PE.; Buck, AK.; Pande, A.; Löffler, D.; Gernert, M.; Duell, J.; Topp, MS.; Mersi, J.; Waldschmidt, J.; Einsele, H.; Hudecek, M.; Saliba, AE.; Rasche, L.; Kortüm, KM.

Blood Cancer Discov. · 2026

Show abstract

We report a fatal case of parkinsonism following treatment with ciltacabtagene autoleucel (cilta-cel). To investigate underlying mechanisms, we performed a multipronged longitudinal analysis using single-cell RNA (scRNA)/T-cell receptor (TCR) sequencing, flow cytometry, and cytokine measurements including cerebrospinal fluid (CSF) and peripheral blood (PB) samples, spanning more than 6 months after chimeric antigen receptor (CAR) T-cell therapy. Combined clinical and molecular findings revealed a biphasic immunologic process in the CSF. The early phase was characterized by a selective influx of predominantly CD4+ CAR T cells, accompanied by the evidence of endothelial dysfunction, prior to the clinical manifestation of parkinsonism. A second phase was preceded by a locally restricted inflammatory process in the CSF. Subsequently, an increase in the CSF to serum albumin ratio indicated disruption of the blood-brain barrier, coinciding with a pronounced influx of T cells-primarily CAR T cells but also clonally expanded, cytotoxic CD8+ non-CAR T cells-which was associated with neuronal injury and clinical decline.

Single-bacterium RNA-seq protocol to uncover heterogeneous expression of coding and noncoding genes in Bacteroides thetaiotaomicron.

Bornet, E.; Westermann, AJ.

STAR Protoc. · 2026

Show abstract

Single-cell RNA sequencing is increasingly applied to bacterial model species, but a dedicated technique for anaerobic microbiota members of the Bacteroidota phylum has been lacking. Here, working with Bacteroides thetaiotaomicron, we describe experimental steps for transcriptome stabilization, fluorescence-activated cell sorting (FACS) collection, and optimized lysis of single cells from this group of organisms. We detail procedures for reverse transcription of RNAs via the multiple annealing and dC-tailing-based quantitative single-cell RNA sequencing (MATQ-seq) protocol, sensitive Cas9-based depletion of ribosomal sequences, and cDNA library generation. For complete details on the use and execution of this protocol, please refer to Bornet et al..

STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Cancer.

Piseddu, I.; Endres, R.; Lanzl, F.; Hammann, L.; Bérouti, M.; Thaler, M.; Fahr, L.; Fischer, H.; Varlamova, V.; Gärtig, J.; Nixdorf, D.; Layritz, P.; Marx, C.; Hörth, C.; Witte, C.; Bulut, A.; Illig, D.; Senz, AM.; Holdt, L.; Regel, I.; Gottschlich, A.; Subklewe, M.; Mayerle, J.; Anz, D.; Kobold, S.; Linder, A.; Hornung, V.

Gastroenterology. · 2026

Show abstract

Chimeric antigen receptor (CAR) T cells have shown great potential in hematological cancers, but lack efficacy in solid tumors, highlighting the need for novel strategies. Stimulator of interferon genes (STING) activation was shown to inflame the tumor microenvironment, but combination of STING agonists and CAR-T cells might be limited by detrimental outcomes of T cell-intrinsic STING activation. In this study, we evaluated the potential of combining STING agonists and CAR-T cells in the context of pancreatic cancer.

Recognition and remodelling of nucleosomes and hexasomes by the human INO80 complex.

Aggarwal, P.; Sharma, M.; Woike, S.; Kunert, F.; Brem, A.; Moldt, M.; Hopfner, KP.

Nucleic Acids Res. · 2026

Show abstract

The ATP-dependent INO80 chromatin remodeller slides and repositions nucleosomes to shape and maintain chromatin around gene regulatory elements and replication origins. Recent work uncovered capabilities of yeast and fungal INO80 to bind and slide hexasomes, but whether this is a universal feature is unknown. Here, we show that human INO80 also slides hexasomes as efficiently as H2A and H2A.Z nucleosomes. By determining a variety of structures of human INO80 bound to canonical and H2A.Z nucleosomes as well as hexasomes, we reveal a predominantly topological sensing of nucleosomal species with at least three positions depending on entry DNA unwrapping. INO80 spin-rotates around the nucleosomal core particle as a function of entry DNA unwrapping. Different degrees of unwrapped entry DNA lead to two different nucleosomal and one hexasomal locations of INO80, determined by binding of the Snf2 ATPase to entry point of extranucleosomal DNA at the nucleosome/hexasome core. Acidic patch binding by the INO80 subunit IES2 can differentiate between (sub)nucleosomal species, is important for nucleosome but not hexasome sliding, and may sense unwrapped exit DNA. These findings provide structural and mechanistic insights into how human INO80 remodels diverse chromatin substrates in a topology driven manner.

RNF25 confers mRNA damage tolerance by curbing activation of the integrated stress response.

Zhao, S.; Palma-Chaundler, CS.; Engel, CM.; Cordes, J.; Nixdorf, D.; Luo, MY.; Kaya, S.; Suryo Rahmanto, A.; van den Heuvel, D.; Mackens-Kiani, T.; Weickert, P.; Lam, S.; Gupta, V.; Philippou-Massier, J.; Bagarić, I.; Bohlen, J.; Hewitt, G.; Luijsterburg, MS.; Beckmann, R.; Beli, P.; Nedialkova, DD.; Carnie, CJ.; Subklewe, M.; Jackson, SP.; Stingele, J.

Mol Cell. · 2026

Show abstract

Excessive RNA damage activates cellular stress responses, triggering cell death. However, pathways that negatively regulate RNA damage responses are largely uncharacterized. Using genetic screens, we find that the ubiquitin ligase RNF25 provides tolerance to RNA damage caused by the nucleoside analogue azacytidine, a chemotherapeutic agent used to treat acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Mechanistically, we show that azacytidine is incorporated into mRNA, where it causes lesions that stall elongating ribosomes, leading to cytotoxic activation of the GCN2-dependent integrated stress response (ISR). Furthermore, we establish that RNF25 prevents ISR hyperactivation by ubiquitylation of ribosomal protein eS31, thereby suppressing cell death upon azacytidine treatment. Our study reveals an mRNA damage tolerance mechanism that determines cellular survival in response to azacytidine, highlighting RNA damage-induced stress response as a potentially critical component of chemosensitivity in AML and MDS.

An inhibitory RNA checkpoint in TLR7 and TLR8.

Bérouti, M.; Hornung, V.

Nat Immunol. · 2026